Showing 1791-1800 of 5631 results for "".
- Santen Announces Topline Data for DE-128 (MicroShunt) Demonstrating Reductions in IOP and Medication Use in Patients With Glaucomahttps://modernod.com/news/santen-announces-topline-data-for-de-128-microshunt-demonstrating-reductions-in-iop-and-medication-use-in-patients-with-glaucoma/2476840/Santen Pharmaceutical announced the results of INN-005, a prospective, randomized, controlled, single-masked, multicenter study to assess the safety and effectiveness of DE-128 (MicroShunt) standalone, without concomitant cataract extraction. The study compared DE-128 implanted intraoperatively w
- Vyluma Completes Last Patient Visit for Phase 3 CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-completes-last-patient-visit-for-primary-analysis-of-pivotol-phase-iii-champ-study-evaluating-nvk002-for-the-treatment-of-myopia-progression-in-children/2481059/Vyluma announced that the last patient visit has been completed for the primary analysis of the pivotal phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with the FDA, to evaluate whether NVK002 eye drops are safe and eff
- Vertex Aims for “Virtual Clinic Visits” to Keep Ongoing Studies on Track Amid COVID-19 Pandemichttps://modernod.com/news/vertex-aims-for-virtual-clinic-visits-to-keep-ongoing-studies-on-track-amid-covid-19-pandemic/2477483/Vertex Pharmaceuticals said that due to the COVID-19 pandemic, the company is working with clinical trial sites to enable “virtual clinic visits” and home delivery of study drugs to ensure that ongoing trials continue as planned with the correct monitoring and procedures in place. How
- The Vision Council Announces Dates for the 2021 Virtual Executive Summit: January 26–28, 2021https://modernod.com/news/the-vision-council-announces-dates-for-the-2021-virtual-executive-summit-january-26-28-2021/2478440/The Vision Council today announces that the
- Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trialhttps://modernod.com/news/nicox-announces-last-patients-complete-final-visit-in-ncx-470-phase-3-mont-blanc-glaucoma-trial/2481100/Nicox announced that the last patients completed their final (3-month) visit in the Mont Blanc phase 3 clinical trial of NCX 470 0.1% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. A total of
- Santen Announces Initiation of Phase 3 Clinical Program (SPECTRUM) Evaluating Glaucoma Treatment Omidenepag Isopropyl (DE-117)https://modernod.com/news/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension/2479772/Santen announced the initiation of the pivotal phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or o
- Aerie Pharmaceuticals Submits Prior Approval Supplement to FDA to Allow Production of Rocklatan in its Athlone Ireland Facilityhttps://modernod.com/news/aerie-pharmaceuticals-submits-prior-approval-supplement-to-fda-to-allow-production-of-rocklatan-in-its-athlone-ireland-facility/2476897/Aerie Pharmaceuticals announced the submission of a prior approval supplement (PAS) to the FDA to permit production of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the United States in Aerie’s new manufacturing plant in Athlone, Ireland. “Along with t
- Siemens Healthineers and Hill-Rom to Provide Comprehensive Diabetes Care for Primary Care Facilitieshttps://modernod.com/news/siemens-healthineers-and-hill-rom-to-provide-comprehensive-diabetes-care-for-primary-care-facilities/2480156/Siemens Healthineers and Hill-Rom signed a co-marketing agreement to provide a suite of point-of-care diagnostic instruments that, for the first time, enable primary healthcare providers in the United States to bridge gaps in diabetes care and satisfy value-based quality measures in a single offi
- Ocular Therapeutix Announces Completion of Debt Refinancinghttps://modernod.com/news/ocular-therapeutix-announces-completion-of-debt-refinancing/2476236/Ocular Therapeutix announced that it has closed a refinancing of its existing debt by entering into a new $25 million term loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan facility allows for an expansion of the company’s prior $18 million credit facility to $25 mil
- FDA Grants Notal Vision Home OCT System De Novo Marketing Authorizationhttps://modernod.com/news/fda-grants-notal-vision-home-oct-scanly-de-novo-marketing-authorization/2482282/Notal Vision announced that the FDA has granted De Novo authorization for its patient self-operated Scanly Home OCT device. Designated by the FDA as a breakthrough device for patients suffering from wet age-related macular degeneration (AMD), Scanly Home OCT aims to improve persona